STELLA PHARMA CORPORATION (JP:4888)
:4888
Top Page
STELLA PHARMA CORPORATION
(4888)
Select Model
Select Model
Rating:60Neutral
Price Target:
¥616.00
▲(203.45% Upside)
Action:ReiteratedDate:04/05/26
The score is mainly driven by strong top-line growth and improved cash flow alongside a solid balance sheet, which are partially offset by ongoing operating losses and negative profitability. Technical indicators add support via a stronger longer-term trend, while valuation is pressured due to the negative P/E and no provided dividend yield.
Positive Factors
High top-line growth
Sustained, large revenue growth indicates expanding market traction and successful commercialization of products. Over a 2–6 month horizon this supports durable scale benefits: stronger bargaining power, deeper customer adoption, and a clearer path to amortize fixed R&D and SG&A into future margin improvement.
Negative Factors
Persistent unprofitability
Ongoing net losses and negative EBIT mean the business has not yet converted revenue growth into earnings. Persisting unprofitability can erode equity over time, force dilutive financing or debt raises, and constrain reinvestment capacity unless margins improve sustainably.
Read all positive and negative factors
Positive Factors
Negative Factors
High top-line growth
Sustained, large revenue growth indicates expanding market traction and successful commercialization of products. Over a 2–6 month horizon this supports durable scale benefits: stronger bargaining power, deeper customer adoption, and a clearer path to amortize fixed R&D and SG&A into future margin improvement.
Read all positive factors
STELLA PHARMA CORPORATION (4888) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥19.98B
Dividend YieldN/A
Average Volume (3M)332.29K
Price to Earnings (P/E)―
Beta (1Y)0.93
Revenue Growth248.15%
EPS Growth76.92%
CountryJP
Employees44
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-6.00
Shares Outstanding34,034,100
10 Day Avg. Volume566,500
30 Day Avg. Volume332,290
Financial Highlights & Ratios
PEG Ratio1.10
Price to Book (P/B)3.99
Price to Sales (P/S)13.30
P/FCF Ratio93.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
STELLA PHARMA CORPORATION Business Overview & Revenue Model
Company Description
Stella Pharma Corporation engages in the research, development, manufacturing, and distribution of pharmaceuticals. The company develops drugs for boron neutron capture therapy (BNCT). Its product includes SPM-011, a boron-containing drug for BNCT...
How the Company Makes Money
null...
STELLA PHARMA CORPORATION Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
70
Positive
Cash Flow
60
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 991.86M | 961.06M | 269.49M | 229.07M | 100.10M | 205.97M |
| Gross Profit | 871.90M | 828.72M | 203.69M | 192.36M | 50.73M | 165.24M |
| EBITDA | -43.84M | -55.52M | -725.26M | -771.73M | -707.77M | -649.12M |
| Net Income | -135.73M | -140.81M | -763.75M | -778.82M | -767.72M | -659.24M |
Balance Sheet | ||||||
| Total Assets | 5.06B | 5.42B | 3.82B | 4.33B | 4.72B | 2.05B |
| Cash, Cash Equivalents and Short-Term Investments | 2.85B | 3.21B | 2.35B | 2.71B | 3.28B | 1.25B |
| Total Debt | 727.12M | 766.78M | 933.30M | 1.09B | 1.25B | 1.41B |
| Total Liabilities | 2.01B | 2.21B | 1.44B | 1.58B | 1.64B | 1.82B |
| Stockholders Equity | 3.05B | 3.21B | 2.38B | 2.75B | 3.08B | 230.72M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 136.50M | -887.82M | -853.07M | -1.13B | -793.58M |
| Operating Cash Flow | 0.00 | 140.41M | -876.84M | -827.67M | -1.08B | -772.81M |
| Investing Cash Flow | 0.00 | 287.58M | -9.01M | -29.93M | -350.56M | -22.86M |
| Financing Cash Flow | 0.00 | 725.78M | 228.25M | 291.69M | 3.46B | 39.92M |
STELLA PHARMA CORPORATION Technical Analysis
Positive
203.00
Price Trends
477.14
Positive
357.71
Positive
368.59
Positive
Market Momentum
73.65
Positive
48.67
Neutral
19.25
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4888, the sentiment is Positive. The current price of 203 is below the 20-day moving average (MA) of 625.95, below the 50-day MA of 477.14, and below the 200-day MA of 368.59, indicating a neutral trend. The MACD of 73.65 indicates Positive momentum. The RSI at 48.67 is Neutral, neither overbought nor oversold. The STOCH value of 19.25 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4888.
STELLA PHARMA CORPORATION Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | ¥19.98B | -8.45 | ― | ― | 248.15% | 76.92% | |
52 Neutral | ¥11.53B | -12.44 | -26.70% | ― | 172.39% | 8.27% | |
52 Neutral | ¥137.15B | -8.84 | ― | 2.18% | -0.16% | -802.20% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥24.16B | -34.16 | ― | ― | -5.65% | -469.19% | |
50 Neutral | ¥51.71B | -13.30 | ― | ― | -82.33% | 47.73% | |
45 Neutral | ¥18.74B | -11.30 | ― | ― | ― | 11.34% |
* Healthcare Sector Average
JP:4888
STELLA PHARMA CORPORATION
587.00
300.00
104.53%
JP:4571
NanoCarrier Co., Ltd.
153.00
40.00
35.40%
JP:4593
Healios KK
383.00
187.00
95.41%
JP:4599
StemRIM Inc.
299.00
53.00
21.54%
JP:4974
Takara Bio Inc.
1,139.00
420.00
58.41%
JP:7774
Japan Tissue Engineering Co., Ltd.
595.00
219.00
58.24%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.